Sentence examples for sustained headache from inspiring English sources
A repeated measures logistic regression analysis found that sustained headache response at 24 hours, averaged across 3 attacks, was significantly higher on both E40 vs. placebo (49% vs. 32%; p < 0.001) and E80 vs. placebo (43% vs. 11%; p < 0.001).
Assessed by the outcome measure sustained headache relief (SHR), arguably an adequate if imperfect outcome [19], aspirin 900 1000 mg has a predicted efficacy of 39% (headache relief at 2 h [HR] 52%) [20] and ibuprofen 400 mg of 45% (HR 57%) [21].
Sumatriptan NS 20 mg provided significantly greater headache relief than placebo at 30 min (42 vs. 33%, respectively; P = 0.046) and 2 h (68 vs. 58%; P = 0.025) post-dose, but did not reach statistical significance at either 1 h (61 vs. 52%; P = 0.087) or for sustained headache relief from 1 to 24 h (P = 0.061).
For acute drugs, we used the clinical endpoint of "sustained headache relief" (SHR), defined as reduction in headache intensity from moderate or severe to mild or none (which we assumed was not associated with disability [10] within 2 hours, without recurrence or further medication during 24 hours (Table 1).
By contrast, eletriptan 40 mg proved to be significantly more effective in reducing headache recurrence than placebo within 24 h (11 vs. 25%, P = 0.028), with post hoc analyses showing statistically significant differences for sustained headache response rates (52 vs. 39%; P = 0.04) and sustained pain-free response rates (22 vs. 10%; P = 0.013) [29].
Sustained headache relief.
Fifteen of the remaining 22 patients reported sustained chronic headache.
Recently, on waking, the patient complained the sudden onset of a sustained tensive headache, unresponsive to conventional treatment.
Although headache responded very well in 43% of patients, sustained long-term headache was seen in the remaining patients, despite normalization of ICP and papilledema.
Zolmitriptan also produced a significant pain-free response at 1 h (27.7 vs. 10.2% in the placebo group, P < 0.001), proving to be significantly superior to placebo in improving pain intensity, pain-free rates, sustained resolution of headache and resolution of associated migraine symptoms.
